CSL Limited (OTCMKTS:CSLLY – Get Free Report)’s stock price reached a new 52-week low on Monday . The stock traded as low as $75.70 and last traded at $79.07, with a volume of 116648 shares traded. The stock had previously closed at $78.95.
Analysts Set New Price Targets
Separately, The Goldman Sachs Group upgraded shares of CSL to a “strong-buy” rating in a report on Thursday, January 16th.
Check Out Our Latest Stock Report on CSLLY
CSL Stock Performance
About CSL
CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants.
Featured Stories
- Five stocks we like better than CSL
- Business Services Stocks Investing
- Homebuilders in Freefall: Bargain Opportunity or Falling Knife?
- What Makes a Stock a Good Dividend Stock?
- The 3 Most Talked About Investments on WallStreetBets Right Now
- How to start investing in penny stocks
- Analyst Targets Signal More Growth in CrowdStrike Stock
Receive News & Ratings for CSL Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CSL and related companies with MarketBeat.com's FREE daily email newsletter.
